PT  - JOURNAL ARTICLE
AU  - S. Chawla
AU  - S. Kim
AU  - L.A. Loevner
AU  - W.-T. Hwang
AU  - G. Weinstein
AU  - A. Chalian
AU  - H. Quon
AU  - H. Poptani
TI  - Prediction of Disease-Free Survival in Patients with Squamous Cell Carcinomas of the Head and Neck Using Dynamic Contrast-Enhanced MR Imaging
AID  - 10.3174/ajnr.A2376
DP  - 2011 Apr 01
TA  - American Journal of Neuroradiology
PG  - 778--784
VI  - 32
IP  - 4
4099  - http://www.ajnr.org/content/32/4/778.short
4100  - http://www.ajnr.org/content/32/4/778.full
SO  - Am. J. Neuroradiol.2011 Apr 01; 32
AB  - BACKGROUND AND PURPOSE: Patients with HNSCC have a poor prognosis and development of imaging biomarkers that predict long-term outcome might aid in planning optimal treatment strategies. Therefore, the purpose of the present study was to predict disease-free survival in patients with HNSCC by using pretreatment Ktrans measured from dynamic contrast-enhanced MR imaging. MATERIALS AND METHODS: Sixty-six patients with HNSCC were recruited from January 2005 to October 2008. Three patients were excluded because they underwent upfront neck dissection, and 6 patients were excluded due to suboptimal MR imaging data or being lost to follow-up. Disease-free survival was measured in the remaining 57 patients from the end date of chemoradiation therapy. In patients who died, the end point was the date of death, while in surviving patients the date of last clinical follow-up was used as the end point. Pretreatment Ktrans and nodal volume were computed from the largest metastatic node, and median pretreatment Ktrans and volume were used to divide patients into 2 groups (at or above the threshold value [group I] and below the threshold value [group II]. Disease-free survival was analyzed by the Kaplan-Meier method, and the results were compared by using a logrank test with Ktrans and nodal volume as predictors. A P value < .05 was considered significant. RESULTS: Thirteen of 57 patients had died of HNSCC by the last follow-up period (March 31, 2009). Patients with higher pretreatment Ktrans values had prolonged disease-free survival compared with patients with lower Ktrans values (P = .029). However, there was no significant difference in disease-free survival when nodal volume was used as a predictor (P = .599). CONCLUSIONS: Pretreatment Ktrans may be a useful prognostic marker in HNSCC. BWbandwidthCIconfidence intervalDCE-MRIdynamic contrast-enhanced MR imagingFAflip angleFDGfluorodeoxyglucoseHNSCCsquamous cell carcinomas of the head and neckKtransvolume transfer constantPETpositron-emission tomographySUVstandard uptake valueTNMTumor, Node, Metastases